spironolactone has been researched along with dapagliflozin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bachir, N; Boukabous, A; Terki, A; Zaoui, N | 1 |
| Brugaletta, S; Cristóbal, H; Dantas, AP; García de Frutos, P; García-Álvarez, A; Mendieta, G; Ortega, E; Ortega-Paz, L; Ortiz-Perez, JT; Rodriguez, JJ; Sabaté, M; Sandoval, E | 1 |
2 other study(ies) available for spironolactone and dapagliflozin
| Article | Year |
|---|---|
[Impact of Dapagliflozin on echocardiographic parameters in patients with heart failure and reduced ejection fraction: "About a monocentric series of 43 cases"].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aminobutyrates; Benzhydryl Compounds; Biphenyl Compounds; Echocardiography; Glucosides; Heart Failure; Humans; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Spironolactone; Stroke Volume | 2022 |
Direct actions of dapagliflozin and interactions with LCZ696 and spironolactone on cardiac fibroblasts of patients with heart failure and reduced ejection fraction.
Topics: Biomarkers; Fibroblasts; Glycogen Synthase Kinase 3; Heart Failure; Humans; Interleukin-6; Matrix Metalloproteinase 9; Proto-Oncogene Proteins c-akt; Sodium-Glucose Transporter 2; Spironolactone; Stroke Volume; Valsartan | 2023 |